Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) announced that its equity-affiliated company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed a Phase I clinical trial for its independently developed ZG-002 tablets, conducted with the approval of the National Medical Products Administration. The clinical study report has recently been received. ZG-002 is a novel drug with a new chemical structure developed by Zhigen Pharmaceutical for the treatment of autoimmune diseases and is classified as a Category 1 new drug. It is currently intended for the treatment of moderate to severe plaque psoriasis. The Phase I trial primarily aimed to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 tablets in healthy adult subjects. Results indicated that the tablets demonstrated favorable safety and tolerability at the administered dose, frequency, and treatment duration, with clear and well-defined pharmacokinetic characteristics. The clinical data obtained from this study support further exploratory clinical research in patient populations.